warning about possible hepatic failure with Serzone

January 2002

The FDA is now warning about possible hepatic failure with Serzone. In fact, you'll see a new "black-box" warning in the package insert.

The incidence of hepatic failure is very rare...one case for every 250,000 to 300,000 patients using Serzone (nefazodone) for one year.

But this rate is about 4 times higher than expected.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote